Neuren Pharmaceuticals Limited (NURPF) Financial Statements
Neuren Pharmaceuticals Limited Financial Overview
Neuren Pharmaceuticals Limited's market cap is currently $1.81B. The company's EPS TTM is $0.16; its P/E ratio is 128.62; and it has a dividend yield of 0.74%. Neuren Pharmaceuticals Limited is scheduled to report earnings on February 24, 2027, and the estimated EPS forecast is $0.20. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 64.63M | $ 213.24M | $ 231.93M | $ 14.55M | $ 3.20M |
| Gross Profit | $ 64.61M | $ 213.22M | $ 205.17M | $ 14.54M | $ 3.19M |
| Operating Income | $ 22.02M | $ 175.55M | $ 172.49M | $ -1.60M | $ -11.43M |
| EBITDA | $ 22.05M | $ 175.57M | $ 199.26M | $ -670.00K | $ -10.98M |
| Net Income | $ 30.44M | $ 142.04M | $ 157.08M | $ 184.00K | $ -7.79M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 296.12M | $ 222.24M | $ 228.54M | $ 40.18M | $ 36.78M |
| Total Assets | $ 342.86M | $ 409.71M | $ 247.97M | $ 43.27M | $ 40.06M |
| Total Debt | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Net Debt | $ -4.23M | $ -3.15M | $ -17.09M | $ -40.18M | $ -36.78M |
| Total Liabilities | $ 4.41M | $ 45.80M | $ 42.76M | $ 1.68M | $ 803.00K |
| Stockholders' Equity | $ 338.45M | $ 363.90M | $ 205.21M | $ 41.59M | $ 39.25M |
| Cash Flow | |||||
| Free Cash Flow | $ 125.39M | $ -11.28M | $ 184.88M | $ 3.58M | $ -9.98M |
| Operating Cash Flow | $ 125.42M | $ -11.27M | $ 184.93M | $ 3.60M | $ -9.97M |
| Investing Cash Flow | $ -88.01M | $ 4.13M | $ -211.49M | $ -19.00K | $ -10.00K |
| Financing Cash Flow | $ -33.22M | $ -8.78M | $ 3.62M | $ -2.00K | $ 22.18M |
Currency in AUD